The pharmaceutical industry’s dependence on universities and small biotechs as the source of innovation is laid bare in an analysis of the origin of all the novel drugs approved by the European Medicines Agency (EMA) in the three years from 2010 – 2012.
The analysis shows that 49 per cent of the products granted marketing authorisation during this time were originally discovered by the in-house efforts of pharma companies, with the remaining 51 per cent originating elsewhere. However, of the 94 products that received approval, 87 per cent were owned by pharma companies at the point the license was granted.
Image: European Medicines Agency headquarters in London
To read the original article: Drug approvals show SMEs and academia are the source of most innovation - Science|Business
